Barclays analyst Balaji Prasad assigned a Buy rating to Tarsus Pharmaceuticals (TARS – Research Report) today and set a price target of $60.00. The company’s shares closed yesterday at $47.57.

Tarsus Pharmaceuticals (TARS) announced the appointment of Katherine Goodrich, M.D., MHS, Chief Medical Officer of Humana Inc., to its Board of Directors. Published first on TheFly – the ultimate ...

Lee Towers, 82, was fatally injured in the collision outside the Jolly Tars pub in Victoria Road West on Monday, October ...

Tarsus Pharmaceuticals (TARS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

IRVINE, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on ...

The crash took place at the junction of Daisy Bank, close to the Jolly Tars Wetherspoons in Thornton Cleveleys, at around ...

Tarsus Pharmaceuticals TARS is set to give its latest quarterly earnings report on Wednesday, 2024-11-13. Here's what investors need to know before the announcement. Analysts estimate that Tarsus ...

Harbor Capital Advisors Inc. raised its holdings in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 57.5% in the third quarter, according to the company in its most recent filing ...

Good news, fellow Melon fans! It may have taken three years since the series’ received its finale announcement, but thanks to ...

View Tarsus Pharmaceuticals, Inc. (TARS) current and estimated P/E ratio data provided by Seeking Alpha.